← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. GLPG
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

GLPG logoGalapagos N.V. (GLPG) P/E Ratio History

Historical price-to-earnings valuation from 2013 to 2025

Current P/E
4.9
Undervalued
5Y Avg P/E
151.0
-97% vs avg
PE Percentile
15%
Low
PEG Ratio
N/A
N/A
TTM EPS$4.87
Price$27.73
5Y PE Range1.0 - 1038.4
Earnings Yield20.52%

Loading P/E history...

GLPG Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
4.9vs151.0
-97%
Cheap vs History
vs. Healthcare
4.9vs22.3
-78%
Below Sector
vs. S&P 500
4.9vs25.1
-81%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 333% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 8, 2026, Galapagos N.V. (GLPG) trades at a price-to-earnings ratio of 4.9x, with a stock price of $27.73 and trailing twelve-month earnings per share of $4.87.

The current P/E is 97% below its 5-year average of 151.0x. Over the past five years, GLPG's P/E has ranged from a low of 1.0x to a high of 1038.4x, placing the current valuation at the 15th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.3x, GLPG trades at a 78% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.

Relative to the broader market, GLPG trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GLPG DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GLPG P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ACAD logoACADACADIA Pharmaceuticals Inc.
$4B9.9Lowest-+68%
HALO logoHALOHalozyme Therapeutics, Inc.
$8B25.51.11-25%
EXEL logoEXELExelixis, Inc.
$12B16.60.32Best+58%
INCY logoINCYIncyte Corporation
$20B15.3-+4173%Best
ABBV logoABBVAbbVie Inc.
$358B85.5--1%
LLY logoLLYEli Lilly and Company
$921B42.51.47+96%
PFE logoPFEPfizer Inc.
$151B19.5--4%
BMY logoBMYBristol-Myers Squibb Company
$115B16.3-+178%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

GLPG Historical P/E Data (2013–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$32.70$4.846.8x-96%
FY2024 Q4$27.50$1.0625.9x-83%
FY2024 Q2Sun Jun 30 2024 00:00:00 GM$24.78$1.0224.3x-84%
FY2024 Q1Sun Mar 31 2024 00:00:00 GM$32.20$0.9633.6x-78%
FY2022 Q3Fri Sep 30 2022 00:00:00 GM$42.64$0.09473.8x+214%
FY2020 Q2$197.29$1.74113.4x-25%
FY2020 Q1$195.92$2.6573.9x-51%
FY2019 Q4$206.83$2.5082.7x-45%
FY2019 Q3Mon Sep 30 2019 00:00:00 GM$152.66$4.5533.6x-78%
FY2017 Q1Fri Mar 31 2017 00:00:00 GM$86.19$0.081038.4x+587%
FY2016 Q4Sat Dec 31 2016 00:00:00 GM$64.19$1.1655.2x-63%
FY2013 Q3Mon Sep 30 2013 00:00:00 GM$21.13$20.641.0x-99%

Average P/E for displayed period: 151.0x

See GLPG's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is GLPG Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare GLPG vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

GLPG — Frequently Asked Questions

Quick answers to the most common questions about buying GLPG stock.

Is GLPG stock overvalued or undervalued?

GLPG trades at 4.9x P/E, below its 5-year average of 151.0x. At the 15th percentile of historical range, the stock is priced at a discount to its own history.

How does GLPG's valuation compare to peers?

Galapagos N.V. P/E of 4.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.

What is GLPG's PEG ratio?

GLPG PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2025.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

GLPG P/E Ratio History (2013–2025)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.